Steven H. Stein

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Angelo Di Leo, Henry Gómez, Zeba Aziz et al. · Journal of Clinical Oncology · 2008 · 421 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez et al. · Journal of Clinical Oncology · 2008 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>HLA-DQA1</i> * <i>02:01</i> Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer

Colin F. Spraggs, L. R. Budde, Linda P. Briley et al. · Journal of Clinical Oncology · 2011 · 277 citations

Medicine, Genetics, Oncology +17

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu et al. · Annals of Oncology · 2009 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16

Lapatinib Antitumor Activity Is Not Dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpressing Breast Cancers

Wenle Xia, Intisar Husain, Lei-Hua Liu et al. · Cancer Research · 2007 · 147 citations

Medicine, Oncology, Pharmacology +17